Novo Nordisk A/S
NVO
$122.71
-$0.04-0.03%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 9.51B | 8.58B | 7.93B | 7.69B | 6.61B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.51B | 8.58B | 7.93B | 7.69B | 6.61B |
| Cost of Revenue | 1.45B | 1.42B | 1.15B | 1.18B | 1.13B |
| Gross Profit | 8.06B | 7.16B | 6.79B | 6.51B | 5.47B |
| SG&A Expenses | 2.69B | 2.06B | 2.25B | 1.94B | 2.07B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -433.10K | -14.31M | 2.19M | -4.75M | -59.48M |
| Total Operating Expenses | 5.44B | 4.65B | 4.44B | 4.09B | 4.15B |
| Operating Income | 4.07B | 3.93B | 3.49B | 3.60B | 2.45B |
| Income Before Tax | 3.99B | 4.10B | 3.54B | 3.56B | 2.24B |
| Income Tax Expenses | 816.66M | 815.64M | 705.13M | 709.33M | 374.17M |
| Earnings from Continuing Operations | 3.17B | 3.28B | 2.84B | 2.85B | 1.87B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.17B | 3.28B | 2.84B | 2.85B | 1.87B |
| EBIT | 4.07B | 3.93B | 3.49B | 3.60B | 2.45B |
| EBITDA | 4.28B | 4.30B | 3.81B | 3.85B | 2.63B |
| EPS Basic | 0.71 | 0.73 | 0.63 | 0.63 | 0.41 |
| Normalized Basic EPS | 0.59 | 0.57 | 0.49 | 0.50 | 0.34 |
| EPS Diluted | 0.71 | 0.73 | 0.63 | 0.63 | 0.41 |
| Normalized Diluted EPS | 0.58 | 0.57 | 0.49 | 0.49 | 0.34 |
| Average Basic Shares Outstanding | 4.46B | 4.48B | 4.49B | 4.50B | 4.51B |
| Average Diluted Shares Outstanding | 4.48B | 4.49B | 4.50B | 4.51B | 4.52B |
| Dividend Per Share | 0.92 | 0.00 | 0.44 | -- | 0.56 |
| Payout Ratio | 0.00% | 59.75% | 0.00% | 92.55% | 0.00% |
